pharmaphorum Podcast
1) Policy in Focus: Trump’s MFN deals, FDA vouchers, and the government shutdown
At the end of September, President Trump invited Pfizer CEO Albert Bourla to the Oval Office to announce that the company and the administration had reached a "deal" on most-favoured nations drug pric...Show More
2) Biotech’s biggest challenge isn’t scientific, but political – with James Roosevelt Jr
Amid historic advances in cell-based therapies and precision medicine, biotech’s biggest challenge isn’t scientific, it’s political. In a new pharmaphorum podcast, James Roosevelt Jr, a longtime healt...Show More
3) On targeted radiotherapeutics, with Marc Hedrick
Radiation has for over a century been considered one of the most powerful methods of destroying cancer. But, even now, ways to deliver significant doses to a tumour without damaging normal surrounding...Show More
4) Towards one, cohesive AI workflow: In conversation with Ilya Burkov
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Ilya Burkov, global head of healthcare & life sciences at Nebius, a company building one of the world’s leading AI infrastructure c...Show More
5) Collaborating on a connected platform journey, with Alexander Alex and Florian Schnappauf
Bayer and Veeva have partnered for several years across commercial, R&D, and quality functions. But recently Bayer migrated to Veeva’s Vault CRM, taking that relationship, and Bayer’s connected platfo...Show More
6) ESMO25: Patient-centric oncological futures with Boehringer Ingelheim
As pharmaphorum reported during ESMO 2025, fresh from a return to oncology with the FDA approval of Hernexeos as a treatment for HER2-positive non-small cell lung cancer (NSCLC), Boehringer Ingelheim ...Show More
7) Smoothing a contract pathway through uncertainty: In conversation with Neal Masia
Back in June, pharmaphorum spoke with Entity Risk’s CEO and co-founder, Neal Masia, a leading health economist, about the unknowns unfolding in the US following the commencement of the second Trump ad...Show More
8) FH25: On the future of health, with Frontiers Health Chairman Roberto Ascione
In the final episode of our special Frontiers Health limited series of the pharmaphorum podcast, web editor Nicole Raleigh speaks with the Chairman of Frontiers Health, Robert Ascione. Ascione - a ser...Show More
9) Allosteric small molecule therapies in PD, with Gene Mack
As Gain Therapeutics announces positive Phase 1b results for its lead compound, GT-02287, pharmaphorum looks back to a conversation with the company’s CEO Gene Mack earlier in the year, discussing all...Show More
10) FH25: Jessica DaMassa on hosting, hype, and health innovation
As one of Frontiers Health’s most recognisable faces (and voices), Jessica DaMassa, founder of WTF Health and long-time emcee of the conference, has had a front-row seat to the events evolution over t...Show More